NCT04742374CompletedEarly phase 1
Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Comparison of the Effects of 2 Therapeutic Plasmapheresis Techniques: Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). A Monocentric Prospective Study With a Single-Case Experimental Design
Source: ClinicalTrials.gov · Last updated 10 Dec 2025
Brief summary (registry, in English)
CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have been described. Treatments include corticotherapy, IVIg and plasmapheresis but the latter's action mechanisms remain unclear. Plasmapheresis supposedly removes toxic agents like antibodies from plasma but it is uncertain whether it has an immune-modulating effect. Also, the refining mechanisms of the two main plasmapheresis techniques - single plasma exchange and double filtration plasmapheresis (DFPP) - are different and unclear. This study aims to compare the evolution of peripheral lymphocyte profiles in patients with CIDP according to their treatment (single centrifugation plasmapheresis or DFPP) to better grasp the action mechanisms of both techniques.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 26 Jan 2021
- Start date
- 12 Mar 2021
- Primary completion date
- 18 Dec 2023
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- NCT number
- NCT04742374
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 8
- From 12 Mar 2021 to the primary completion date, 18 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Healthy subject with chronic pathology or drug treatment
Age
- Patients Under the age of 18.
Other
- Patients under immunosuppressive treatment for less than 3 months.
- Patients participating in Category 1 research involving human subjects.
- Patients in an exclusion period determined by another study.
- Patients under legal protection, guardianship or curatorship.
- Patients unable to express consent.
- Patients for whom it is impossible to give informed information.
- Pregnant, parturient or breastfeeding patients.
Who the study is looking for
- Patients with confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) without pathogenic antibodies and stable under therapeutic plasmapheresis with one session every 2-3 weeks for at least two months.
- Patients who have given free written informed consent.
- Patients who have signed the consent form.
- Patients affiliated to or beneficiaries of a health insurance scheme.
- Adult patients (≥18 ans).
- Healthy subjects of the same age and sex
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Olivier MORANNE Coordinator of this site? Confirm its status | Nîmes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.